FIG. 5.

Coproduced IκB-α down-regulated NF-κB activities and antiapoptotic effects in core-producing cells. Combinations of 4.5 μg of pCMV-Core, 4.5 μg of pCMV-IκB, and 1.5 μg of pMacsK^k and pKS+/CMV were transfected into HepG2 (upper panels) or MCF-7 (middle panels) cells with a total of 10.5 μg of expression plasmids. In Jurkat cells (lower panels), a total of 2 × 10⁶ cells were transfected with a total of 4.9 μg of expression plasmids, including 2.1 μg of pCMV-Core, 2.1 μg of pCMV-IκB, and 0.7 μg of pMacsK^k and pKS+/CMV with 20 μl of SuperFect reagent. After the concentration procedure, HepG2 and Jurkat cells were treated with anti-Fas and MCF-7 cells were treated with TNF-α (right panels). Cell viability was assayed as indicated for Fig. 1. HepG2 and MCF-7 cells were cotransfected with 0.25 μg of pNF-κB-Luc and 0.75 μg of pCMV-Core, pCMV-IκB, or pKS+/CMV with a total of 1.75 μg of expression plasmids. In Jurkat cells, a total of 4.9 μg of expression plasmids, including 0.7 μg of pNF-κB-Luc, and 2.1 μg of pCMV-Core, pCMV-IκB, or pKS+/CMV were transfected. The luciferase activity was measured as described in the legend to Fig. 3.